Cleared Traditional

K863317 - ENZYGNOST ANTI-VZV IGG TEST

K863317 is an FDA 510(k) clearance for ENZYGNOST ANTI-VZV IGG TEST, manufactured by Behring Diagnostics, Inc.. The device is a Class 2 Microbiology device with product code GQX cleared through the Traditional 510(k) pathway after a 239-day FDA review.

K863317 · Behring Diagnostics, Inc. · Microbiology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 1987
Decision
239d
Days
Class 2
Risk

K863317 is an FDA 510(k) clearance for the ENZYGNOST ANTI-VZV IGG TEST. Classified as Antiserum, Cf, Varicella-zoster (product code GQX), Class II - Special Controls.

Submitted by Behring Diagnostics, Inc. (La Jolla, US). The FDA issued a Cleared decision on April 22, 1987 after a review of 239 days - an extended review cycle.

This device falls under the Microbiology FDA review panel, regulated under 21 CFR 866.3900 - the FDA microbiology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Microbiology review framework, consistent with the majority of Class II 510(k) submissions.

View all Behring Diagnostics, Inc. devices

FDA 510(k) Submission Details - K863317

510(k) Number K863317 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 26, 1986
Decision Date April 22, 1987
Days to Decision 239 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
137d slower than avg
Panel avg: 102d · This submission: 239d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

GQX Device Classification - Class 2, Special Controls

Product Code GQX Antiserum, Cf, Varicella-zoster
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.3900
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Microbiology devices follow this clearance model.

Regulatory Peers - GQX Antiserum, Cf, Varicella-zoster

Devices cleared under the same product code (GQX) and FDA review panel - the closest regulatory comparables to K863317.
VARICELLA-ZOSTER VIRUS DIRECT IMMUNOFLUORESCENCE ASSAY
K951799 · Light Diagnostics · Mar 1996
VZV IGM TEST
K911301 · Gull Laboratories, Inc. · Jul 1991
VZV TEST
K875358 · Gull Laboratories, Inc. · Mar 1988
ORTHO VARICELLA-ZOSTER VIRUS IDENT.
K841526 · Ortho Diagnostic Systems, Inc. · Jun 1984
VARICELLA-ZOSTER FA LABELLED (8-321 RF)
K770806 · Flow Laboratories, Inc. · May 1977
VARICELLA-ZOSTER FA LABELED PRESERUM
K770810 · Flow Laboratories, Inc. · May 1977